The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt

Statistics in Medicine

Volumn 30, Issue 19, 2011, Pages 2409-2421

  Royston, Patrick ^a   Parmar, Mahesh K B ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Flexible parametric survival models; Hazard ratio; Non proportional hazards; Randomized controlled trials; Restricted mean survival time; Time to event data

Indexed keywords

ARTICLE; CANCER RESEARCH; CANCER SURVIVAL; DATA ANALYSIS; DRUG EFFECT; HAZARD RATIO; KAPLAN MEIER METHOD; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARAMETRIC TEST; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL; SURVIVAL TIME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 80955180013     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4274     Document Type: Article

References (19)

1. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Statistics in Medicine 1982; 1:121-129.
2. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics 1983; 39:499-503.
3. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwak Y, Ohe Y, Yang J-J, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine 2009; 361:947-957.
4. Schemper M, Wakounig S, Heinze G. The estimation of average hazard ratios by weighted Cox regression. Statistics in Medicine 2009; 28:2473-2489.
5. Kalbfleisch JD, Prentice RL. Estimation of the average hazard ratio. Biometrika 1981; 68:105-112.
6. Irwin JO. The standard error of an estimate of expectation of life, with special reference to expectation of tumourless life in experiments with mice. Journal of Hygiene 1949; 47:188-189.
7. Zucker DM. Restricted mean life with covariates: modification and extension of a useful survival analysis method. Journal of the American Statistical Association 1998; 93:702-709.
8. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R, Morris C, Mathur V, Varnauskas E, Chalmers TC. Effect of coronary artery bypass graft on survival: overview of ten-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344:563-570.
9. Andersen PK, Hansen MG, Klein JP. Regression analysis of restricted mean survival time based on pseudo-observations. Lifetime Data Analysis 2004; 10:335-350.
10. Perme MP, Andersen PK. Checking hazard regression models using pseudo-observations. Statistics in Medicine 2008; 27:5309-5328.
11. Parner ET, Andersen PK. Regression analysis of censored data using pseudo-observations. Stata Journal 2010; 10:408-422.
12. Klein JP, Gerster M, Andersen PK, Tarima S, Perme MP. SAS and R functions to compute pseudo-values for censored data regression. Computer Methods and Programs in Biomedicine 2008; 89:289-300.
13. Royston P, Parmar MKB. Flexible proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Statistics in Medicine 2002; 21:2175-2197.
14. Royston P. Flexible parametric alternatives to the Cox model, and more. Stata Journal 2001; 1:1-28.
15. Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata Journal 2009; 9:265-290.
16. Shen Y, Fleming TR. Weighted mean survival test statistics: a class of distance tests for censored survival data. Journal of the Royal Statistical Society (Series B) 1997; 59:269-280.
17. Medical Research Council Renal Cancer Collaborators, Interferon- α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999; 353:14-17.
18. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine 1996; 334:1-6.
19. Andersen PK, Perme MP. Pseudo-observations in survival analysis. Statistical Methods in Medical Research 2010; 19:71-99.